Chartered Institute of Management Accountants

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study

Plain Language SummaryWhat is this summary about?This summary describes how well talquetamab worked and its safety at a median (midpoint) of 17–26 months follow-up from the MonumenTAL-1 study, which tested talquetamab treatment for a type of cancer called relapsed/refractory mult...